Mentorship Award #3: Hypertrophic Cardiomyopathy sponsored by Bristol Myers Squibb

Congratulations to Mentor Forum Kamdar MD PhD and Mentee Dr Marilena Giannoudi, who will investigate best practices in the treatment and management of HCM.

#EA2024 #WIC

We look forward to being part of the Black Health Matters Spring Health Summit & Expo in Washington, D.C. on April 13, 2024 where we'll speak to the power of advocacy in #healthequity #BHMSpringSummit24

#MEDIA : Targeted therapy combination for KRAS G12C-mutated locally advanced or metastatic colorectal cancer demonstrates promising Phase 1/2 clinical results; data presented at #AACR24 bit.ly/3J8ANj5

Our Phase 3 Librexia program, in collaboration with J&J Innovative Medicine, is the most comprehensive FXIa development program today. Learn more about the work we are doing in this recent The Wall Street Journal article: bit.ly/3VOep67 #ACC24

#MEDIA : Announcing pooled interim long-term safety and metabolic outcomes results from the Phase 3 EMERGENT program in adults living with schizophrenia at #SIRS2024 . bit.ly/3PSHqtD

#MEDIA : Today, we presented interim long-term efficacy results from the Phase 3 EMERGENT-4 trial in adults living with schizophrenia at #SIRS2024 . bit.ly/4aMn7pJ

We’ll be attending #ACC24 , hosted by American College of Cardiology, this weekend! Visit our booth #2115 to learn about our Phase 3 Librexia program in partnership with J&J Innovative Medicine, designed to research outcomes in patients with thrombotic diseases.

#MEDIA : The U.S. FDA has approved our personalized therapy in earlier lines of treatment for adult patients with relapsed or refractory #multiplemyeloma . bit.ly/3TEpuni

#MEDIA : European Commission expands approval of our first-in-class #anemia therapy to include the first-line treatment of adults with lower-risk myelodysplastic syndromes. bit.ly/3vASVyQ

Making an impact on society has been one of our cornerstones for more than 130 years. Explore our 2023 #ESG Report, which shares an evolved strategy and the progress we’ve made to advance patient access, product innovation, and global inclusion: bit.ly/3TZS0RJ

#MEDIA : Announcing positive results from the Phase 3 pivotal KRYSTAL-12 confirmatory trial evaluating a targeted therapy for patients with pretreated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer bit.ly/43Cx4n4

Today BMS announced a $1.8M initiative to address inequality in global healthcare. This new grant program will help address social determinants of health in #Brazil , #India , #Thailand and #UK . Learn more: bit.ly/3TvrzSF

Clinical trials help answer important scientific questions and allow us to gain a better understanding about the efficacy and safety of potential medicines for patients affected by #multiplemyeloma . #mmsm

#MEDIA : We’re presenting data at #ACC24 including new research across our #cardiovascular portfolio that seeks to address unmet needs for patients living with cardiovascular diseases. bit.ly/3PCYWlf

#MEDIA : The European Commission approved our #CARTCellTherapy in earlier lines of treatment for a type of blood cancer. bit.ly/3VmP1Ec

#MEDIA : Announcing positive results from the Phase 3 CheckMate -9DW trial evaluating our immunotherapy combination for the first-line treatment of patients with advanced hepatocellular #carcinoma . bit.ly/43qkM16

We’re empowering patients living with moderate to severe plaque #psoriasis to honor their unique identities and journeys, including having meaningful conversations with their dermatologists about their condition and treatment options. Learn more: bit.ly/3Vp1S8T

Today marks the completion of our Karuna Therapeutics transaction. We are excited about the potential of our neuro pipeline to transform the lives of millions of patients with neurological and neuropsychiatric diseases. Read more: bit.ly/3vhZCFL

#MEDIA : The FDA’s ODAC voted in favor of our #CARTCellTherapy in earlier lines of treatment for a type of blood cancer, demonstrating a favorable benefit/risk profile. bit.ly/4ceUxib

#MEDIA : U.S. FDA granted accelerated approval for our personalized therapy to treat relapsed or refractory chronic lymphocytic leukemia ( #CLL ) or small lymphocytic lymphoma ( #SLL ) – marking a significant advancement for patients with a critical unmet need. bit.ly/3VjKrq9